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Few countries in Africa currently include rubella-containing vaccination
(RCV) in their immunization schedule. The Global Alliance for Vaccines
Initiative (GAVI) recently opened a funding window that has motivated
more widespread roll-out of RCV. As countries plan RCV introductions, an
understanding of the existing burden, spatial patterns of vaccine coverage,
and the impact of patterns of local extinction and reintroduction for rubella
will be critical to developing effective programmes. As one of the first
countries proposing RCV introduction in part with GAVI funding, Madagas-
car provides a powerful and timely case study. We analyse serological data
from measles surveillance systems to characterize the epidemiology of rubella
in Madagascar. Combining these results with data on measles vaccination
delivery, we develop an age-structured model to simulate rubella vaccination
scenarios and evaluate the dynamics of rubella and the burden of congenital
rubella syndrome (CRS) across Madagascar. We additionally evaluate the dri-
vers of spatial heterogeneity in age of infection to identify focal locations
where vaccine surveillance should be strengthened and where challenges to
successful vaccination introduction are expected. Our analyses indicate that
characteristics of rubella in Madagascar are in line with global observations,
with an average age of infection near 7 years, and an impact of frequent
local extinction with reintroductions causing localized epidemics. Modelling
results indicate that introduction of RCV into the routine programme alone
may initially decrease rubella incidence but then result in cumulative increases
in the burden of CRS in some regions (and transient increases in this burden
in many regions). Deployment of RCV with regular supplementary cam-
paigns will mitigate these outcomes. Results suggest that introduction of
RCV offers a potential for elimination of rubella in Madagascar, but also
emphasize both that targeted vaccination is likely to be a lynchpin of this
success, and the public health vigilance that this introduction will require.1. Introduction
Rubella is a directly transmitted immunizing infection that usually occurs
during childhood and is associated with low morbidity and mortality. Infection
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Figure 1. Theoretical expectations for RCV coverage and the burden of CRS. In a
classic SIR framework, the dynamics of susceptibles are captured by dS/dt¼
m(12 v)2 bSI2 mS; and infected by dI/dt ¼ bSI2 gI2 mI; where
m is the birth and death rate, total population size as taken as N¼ 1, v is
vaccination coverage of the birth cohort, g is the generation time of the infection
and the transmission rate is b ¼ R0(g þ m). To capture rubella dynamics, we
set g to 18 days21, R0 ¼ 5, and chose m¼ 30 per 1000 per year. (a) The
equilibrium proportion of infected individuals I* (y-axis) is defined by I*¼
m[(12 v)R02 1]/b and thus declines with increasing vaccination coverage
(x-axis). (b) Conversely, the average age of infection A (y-axis) increases, follow-
ing R0¼ G/A, where G is the inverse of the unvaccinated birth rate, G¼
1/[m(12 v)]. (c) This conjunction of declining incidence but increasing average
age of infection has the potential to yield a situation where more cases are occur-
ring in women of childbearing age, even though the total number of cases is
declining. As a result, the ratio of the equilibrium burden of CRS in the presence
of vaccination relative to the equilibrium burden of CRS if no vaccination has
occurred (y-axis) may first increase with vaccination coverage relative to the scen-
ario of no vaccination (indicated by the horizontal grey line); eventually declining
when incidence is sufficiently low to offset the increase in the average age of
infection. (Results in the last panel are hypothetical; exact values will depend
on the variance and skew of the distribution of age of infection; as well as pat-
tern of fertility over age). This pattern of increasing CRS burden with increasing
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which is associated with multiple disabilities that can require
lifelong care [1], including hearing impairment, cataracts and
congenital heart disease [2].
A relatively inexpensive, high efficacy vaccine that pro-
vides lifelong immunity to rubella and can easily be
combined as measles–rubella (MR), or measles–mumps–
rubella (MMR) has been available for 50 years. Although rou-
tine rubella vaccination can prevent CRS, inadequate
vaccination coverage may actually increase CRS cases by
increasing the average age of infection [3]; this occurs because
vaccination short of the threshold required for elimination
effectively reduces incidence in the population, thus reducing
the risk of infection and delaying time to the first infection
(figure 1). Consequently, introduction of rubella-containing
vaccine (RCV) has been limited globally. Recent efforts for
the control and elimination of measles have spurred renewed
interest in the potential for rubella control, because the two
vaccines are easily combined, and overall measles vaccination
coverage levels have been climbing [4]. In addition, the
Global Alliance for Vaccines Initiative (GAVI) has recently
opened a funding window for rubella vaccination [5]. Mada-
gascar is one of the countries that has successfully applied for
this funding.
For all low- and middle-income countries that take advan-
tage of the GAVI funding window, introduction of RCV will
likely be shaped by the context of measles childhood immu-
nization efforts. In Madagascar, measles vaccination was
introduced into the routine programme in 2004. Coverage
increased steeply until political upheavals in 2009, at which
point levels fell again; currently, measles vaccination coverage
(defined as the number of doses delivered divided by the
target population size) today hovers around 85% in Madagas-
car [6]. One of the perceived possible advantages of
introduction of RCV is strengthened investment in measles
programmes [7], an important potential public health benefit
in Madagascar. However, these benefits must be balanced
with broader consequences, including potential negative out-
comes of introduction of RCV for the burden of CRS [8].
Birth rates in Madagascar remain relatively high (more than
30 per 1000 per year [9]), and theory suggests that high birth
rates are associated with a low burden of CRS in the absence
of vaccination [10], making investment for RCV less of a
public health priority. Further, with high birth rates, and par-
ticularly in the context of high transmission, a very high
threshold of vaccination coverage is required to move
beyond coverage levels that result in increases in the CRS
burden [10]. A final complication is that even where coverage
is sufficiently high to ensure a country-scale reduction in the
CRS burden, heterogeneous vaccination coverage might
result in increases in inequity in the burden of CRS [11,12].
Local rubella extinction allows susceptible women to age
into their childbearing years while still retaining susceptibility,
thus creating regions at high risk for CRS. Vaccination may
alter the flow of infected individuals into these high-risk
regions to further elevate the burden of CRS [11].
Understanding key features of the context, and delineat-
ing the possible consequences of introduction of RCV into
Madagascar has implications for other low-income countries.
Many countries across the AFRO region are considering
introduction of RCV, and although the WHO position piece
on rubella vaccination emphasizes the importance of immu-
nizing women of childbearing age [13], GAVI is not
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Figure 2. The epidemiology of rubella in Madagascar. (a) Reported number of cases through time for the entire country; (b) associated estimates of transmission
from the TSIR model; (c) age distribution of infection, and average age of infection (vertical lines) associated with each of the six provinces and (d ) Map of incidence
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routine childhood immunization programmes. As a result,
few countries are investigating this possibility. Understand-
ing the risks associated with a focus on routine vaccination
alone, when compared with routine vaccination with invest-
ments into regular campaigns, is of considerable public
health relevance [14]. It is possible that the particular demo-
graphic and vaccination profiles of a given region may be
such that routine vaccination will result in serious conse-
quences [15]; and it is important that we consider all
possible outcomes when designing public health policy.
Detailed characterization of a country’s situation before
and after introduction of RCV remains the exception in the
current landscape of global health. Using existing data from
Madagascar, we are in a position to document the current
status of the burden of CRS (thus providing a baseline for
further evaluation), identify key surveillance needs and
develop a better understanding of the risks in a broader
public health context.
Here, we draw on data from a range of sources to ask
(i) What is the current epidemiology of rubella in Madagascar?
(ii) What is the current context of measles vaccination deliveryin Madagascar, and what does this mean for how RCV will be
deployed? and (iii) What are the likely consequences of intro-
duction of RCV on both the incidence of rubella and the
burden of CRS? We conclude by discussing what these
patterns suggest for rubella roll-out more broadly, across
low-income countries likely to capitalize on the GAVI initiative.2. Material and methods
2.1. Epidemiology of rubella in Madagascar
Rubella data were obtained via the system of general surveillance
for measles in Madagascar (figure 2). For all patients presenting
with fever, generalized rash, and either cough, coryza or con-
junctivitis, a serum specimen was collected, and subsequently
tested using standard serological techniques at the WHO
national reference laboratory located at the Institut Pasteur of
Madagascar in Antananarivo. Samples that were measles IgM
negative were tested for rubella IgM antibody. These assays sup-
plied information about the age range and incidence of rubella
through time across the six major provinces of Madagascar,
and a Time-series Susceptible–Infected–Recovered (TSIR)































Figure 3. The burden of CRS. (a) Simulated deterministic burden of CRS over 30 years in the absence of vaccination for each region; and (b) Current routine
vaccination coverage values per region (taking the lower conservative scale of routine vaccination coverage). (c) Simulated deterministic burden of CRS over 30
years following introduction of routine vaccination only (set at the conservative lower bound) divided by the simulated deterministic burden of CRS obtained
in the absence of vaccination (shown in figure 3a)). Where the ratio exceeds 1, the introduction of vaccination has resulted in an increase in the burden of
CRS. (d ) Similarly, ratio of the simulated deterministic burden of CRS over 30 years following introduction of routine vaccination with a starting campaign reaching
up to age 10, and follow-up campaigns to age 5 occurring every 4 years; all campaigns have a coverage of 60%. The full colour scale for ratios encompasses values
more than 1.3 not observed here, but to enable comparison of outcomes with R0 ¼ 8 (electronic supplementary material, figure S6), and detection of areas where
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rubella cases that are reported (or reporting rate, here denoted r),
as well as the starting proportion susceptible (S), and seasonal
fluctuations in rubella transmission (bs). It would be of consider-
able interest to compare these patterns to the spatial and
temporal trends in incidence of CRS. However, the variety of
symptoms associated with CRS and the multiplicity of possible
alternative causes of many of these symptoms (such as deafness
or cataracts) makes CRS surveillance intractable in low resource
settings where serological testing is a rarity; data on CRS are
not currently available for Madagascar.2.2. Characterizing measles vaccination in Madagascar
We consulted the Ministry of Health (MOH) of Madagascar and
UNICEF for details on recent measles vaccination coverage. Rou-
tine vaccination is provided at most public and private clinics
and aims to vaccinate all children around nine months of age.
Two additional opportunities for vaccination also exist: (i) Sup-
plementary Immunization Campaigns (occurring in 2007, 2010
and 2013) intended to complement routine vaccination and
(ii) mother and child health days, targeting children between 9
and 11 months, which are bi-annual campaigns intended to pro-
vide care to the most remote and vulnerable mother and children
populations in the country. Vaccination services are provided by
the national health authorities (MOH) and non-governmental
organizations, primarily UNICEF. We obtained estimates of rou-
tine immunization coverage from the MOH for each of the 22
regions (figure 3b) of Madagascar in 2014. These data measure
the number of doses distributed in each region divided by the
target population size, and values range from 52% (in the
region of Melaky region) to 92% (in Vakinankaratra region),
with an average of 77% (table 1). Deviations in population size
as well as the uneven success of dose delivery make these uncer-
tain measures of vaccine delivery [16]. To provide a conservative
yet comparable analysis across regions, we therefore used exist-
ing administrative data from 2015, which include doses
delivered up to 7 July 2015. These estimates range from 5% (in
Atsimo-Atsinana) to 70%, (in Vakinankaratra) with an average
of 37% (table 1). The reality of measles vaccination coverage inMadagascar is almost certainly greater than these estimates
suggest, but these values provide a conservative baseline from
which to evaluate areas at risk for increases in the CRS burden
in the event of rubella vaccine introduction.2.3. The burden of congenital rubella syndrome
To project the burden of CRS in Madagascar in each of the
22 regions and evaluate the impact of vaccination programmes,
we simulated the age-structured dynamics of rubella in Mada-
gascar (electronic supplementary material, figure S2). Within
the simulation, we classified individuals by their age (using
monthly age classes up to age 15 and yearly classes thereafter),
and epidemiological status (tracking individuals across
Maternally immune, Susceptible, Infected, Recovered and
Vaccinated classes). We used region-specific birth rates (from
www.worldpop.org.uk), and a mortality curve derived from
UN projections to capture demographic patterns; we set the gen-
eration time of rubella to be two weeks, introduced known
patterns of waning of maternal immunity and vaccine efficacy
[10], and explored different levels of R0 (defined as the average
number of secondary infections from one infected individual in
a completely susceptible population). The range of R0 values
was determined by referencing existing estimates for rubella
(ranging from 2 [17] to 12 [18]) and choosing values consistent
with the age range of rubella observed in the epidemiological
data described above (using the fact that R0 is approx. equal to
G/A, where G is the inverse of the birth rate and A is the average
age of infection [19]). We also introduced reported levels of
routine vaccination coverage for each region for measles from
the two sources described above (table 1), and made the conser-
vative assumption that vaccination coverage in Starting
Campaigns and Supplementary Immunization Activities (SIA)
reaches 60% of the population. The time horizon chosen for
evaluation of the burden of CRS and the impact of vaccination
was 30 years; we also evaluated the number of years during
which the burden of CRS was higher than it would have been
at equilibrium pre-vaccination following introduction of the
vaccine (transient increases).
Table 1. Measles vaccination coverage in Madagascar. Vaccination coverage
in each of the 22 regions, from the 2014 administrative coverage estimates
(i.e. doses delivered divided by target population size); and also showing
the early 2015 coverage, taken as a conservative lower boundary, as this
reﬂects reports on doses delivered only up until June of 2015, and is
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congenital rubella syndrome
The simulations described above provide insight into the deter-
ministic burden of CRS. However, previous work indicates that
stochastic dynamics within the broader ‘metapopulation’, or net-
work of communities across which rubella persists, or goes
extinct and is reintroduced, can result in increased burden in
some locations [12]; these same metapopulation processes can
drive spatial inequity in changes in the burden of CRS following
introduction of the vaccine [11]. Local extinction underpins these
changes in CRS burden by allowing susceptible individuals to
age into later age classes, and potentially their childbearing
years, without exposure to the infection. This leaves them vulner-
able to a potential re-introduction of the infection occurring
during their pregnancies. Consequently, we also sought to ident-
ify areas in Madagascar most likely to be affected by stochastic
metapopulation dynamics. To do this, we evaluated the
number of districts with population sizes less than the expected
Critical Community Size (CCS) for rubella. The CCS describes
the minimum population size required to sustain an immunizing
infection without stochastic extinction [20], an empirical measure
which combines both the theoretical extinction boundary for theinfection (assuming a well-mixed population), but also the
impact of patterns of re-introduction. While by convention, the
CCS is usually framed in terms of total numbers of individuals
[20] in reality, the key value will be number of susceptible indi-
viduals in a community. Nevertheless, to align with previous
work, we focus on total population size and concentrate our
evaluations of the CCS only in non-vaccination settings. We
focused on districts (smaller administrative units than the regions
considered above) in this analysis, because these smaller spatial
scales are more likely to represent reasonably well-mixed popu-
lations. Evidence from South Africa suggests that the CCS for
rubella may be of a similar scale to measles [21], i.e. around
350 000, although data from other countries suggest that it
might be closer to 1 000 000 [12,21,22]; simulation approaches
suggest that this estimate may be biased upwards [21].
Under-reporting of rubella cases in this dataset precludes
direct investigation of the CCS [11], instead we independently
evaluated population sizes and their connectivity for districts
of Madagascar. With gridded population maps from World
Pop (www.worldpop.org.uk), we identified districts with popu-
lation sizes below the upper the range of previous CCS estimates
[11], i.e. 350 000–1 000 000. We then developed expectations for
the number of new arrivals in each location based on classic grav-
ity models [23,24]. We used the travel times between centroids of
districts as the distance [25–27] using geospatial techniques (see
the electronic supplementary material) to develop an accessibil-
ity/travel time matrix. Connectivity is measured based on the
amount of outgoing travel from each location from the gravity
model using travel time distance between district centroids,
which yields an index of connectivity for each location (see the
electronic supplementary material). More remote areas have
fewer trips to other areas of the country. From this, we identified
districts that were both weakly connected (remote) and below the
CCS threshold, taking both the upper and lower ranges of CCS
reported globally. We used stochastic simulations to test expec-
tations for the relationship between connectivity and average
age of infection in a district below the CCS (electronic sup-
plementary material, figure S3) finding that more weakly
connected locations are expected to show higher variance in
the average age of infection. We then plotted average age of
infection reported in the incidence data against our index of con-
nectivity to evaluate the degree to which these estimates are able
to identify locations at risk of later infection associated with
extinction–recolonization dynamics.2.5. Metapopulation dynamics and the potential for
rubella extinction in Madagascar
Madagascar is an island and rubella dynamics are predomi-
nantly driven by national patterns of incidence, extinction and
reintroduction. Data on births and population size for each of
the 22 regions of Madagascar, and our TSIR estimates of season-
ality in rubella transmission, provide us with the means to
simulate stochastic local regional dynamics for rubella. We can
extend these simulations to investigate Madagascar-wide meta-
population dynamics by using the estimates of travel
magnitude between each of the pairs districts (accessibility
matrix) described above. As these measures are relative rather
than absolute [25–27], we first rescaled these measures such
that they resulted in metapopulation dynamics that reflected esti-
mates of the CCS of rubella in the pre-vaccination era within the
range reported for rubella globally (350 000–1 000 000; see the
electronic supplementary material, figure S4). Next, we intro-
duced RCV into this framework at rates reported for measles
vaccination coverage from administrative coverage in 2014, as
well as increased rates, with the aim of identifying the threshold
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3.1. Epidemiology of rubella in Madagascar
Under-reporting in the incidence data affected our ability to
estimate the proportion of the population susceptible to
rubella (see figure 2a and the electronic supplementary
material, S1). However, the TSIR model indicated a clear pat-
tern of seasonality in transmission, with low transmission in
February, June and October, which was robust to the range
of assumptions about starting proportion susceptible
(figure 2b). Surprisingly, the timing of low transmission does
not align with summer school holidays, in contrast to what
has been reported for rubella and other immunizing childhood
infections in many other parts of the world [22,28,29].
Given low reported incidence (figure 2a), we focused our
initial descriptive analysis of the epidemiology of rubella in
Madagascar at the largest administrative scale available, the
six provinces of Madagascar. The average age of infection
of rubella is slightly variable across these provinces, ranging
from 6.4 years in the province of Antananarivo to 8.8 years in
Antsiranana (figure 2c). Average age broadly negatively cor-
relates with province population size (Pearson’s correlation
between log population size and average age of infection
yields r ¼ 20.82, n ¼ 6, p, 0.05), suggesting an underlying
biological driver for this pattern. Two possible drivers of
this average infection age distribution include (i) extinc-
tion–recolonization dynamics, which drive up the average
age of infection in smaller population provinces [12]—
implying that provinces with smaller populations also have
smaller focal population centres, precluding persistence of
rubella or (ii) a higher R0 for rubella in provinces with
larger populations (although see [29] for evidence that
measles, a similar directly transmitted infections, shows no
signature of density-dependent transmission). With the
data available, it is not possible to distinguish between
these two possibilities. Using the approximation R0 ¼ G/A
(which assumes negligible stochastic dynamics), where G is
the inverse of the birth rate, and A is the average age of infec-
tion, the average age of infection in the data yields estimates
of R0 between 3.9 in Antsiranana province and 5.5 in Antana-
narivo province. This range is broadly in line with values
previously reported for this infection [15,30,31].3.2. Consequences of introduction of rubella-containing
vaccination: deterministic simulations
Simulation of region-specific dynamics built around the esti-
mated profile of seasonal transmission (figure 2b) and with
R0 ¼ 5 (see the electronic supplementary material, figure S2
for an example time-series), indicates that in the absence of
vaccination, the number of CRS cases varies across the 22
regions of Madagascar between six new CRS cases (in
Melaky) and 73 (Analamanga) per year; or between 60 and
81 cases per 100 000 births (figure 3a). Introduction of RCV
into the routine programme at the lower reported levels of
administrative coverage (figure 3b) results in a reduction in
the burden of CRS in all but five regions (figure 3c,
Androy, Atsimo-Andrefana, Atsimo-Atsinana, Ihorombe
and Melaky); CRS burden is reduced in all regions when
the less conservative 2014 estimates of coverage are used
(table 1). In both simulations, a number of years of transient
outbreaks with a CRS burden higher than would have beenobserved in the absence of vaccination occur (electronic sup-
plementary material, table S1). If an SIAwith 60% coverage is
introduced at the same time as the start of routine vaccination
against rubella, and maintained at 4 year intervals targeting
up to 5 year olds, then the burden of CRS is successfully
reduced in all 22 regions (figure 3d ), and the transient
increases in the CRS burden also disappear. Parallel results
with R0 ¼ 8 are shown in the electronic supplementary
material, figure S6; for this magnitude of transmission,
more regions are at risk of an increase if routine vaccination
only is introduced; again, public health consequences can
be mitigated by deployment of SIAs. Finally, in this setting,
starting campaigns reaching beyond 10 years of age show
very little improvement relative to those only extending to
10 years of age (results not shown). The full set of results is
shown in the electronic supplementary material, table S1.
3.3. The stochastic burden of rubella: exploring risk
The majority (54%, 61 out of 114 reporting districts) of districts’
populations in Madagascar are below the lower end of the
rubella CCS range (350 000), and all but one are below the
upper threshold of 1 million (99%, 113 out of 114 districts).
Population size and connectivity are strongly correlated
(figure 4a) so many districts are both weakly connected
(remote) and below both the higher and lower threshold of
CCS, shown in figure 4a (electronic supplementary material,
figure S4a indicates the underlying patterns of connectivity),
indicating potential for both local extinction, and a long inter-
val before re-introduction of the rubella infection. Although in
the simplest analysis, local extinction of an infectious disease
seems a desirable outcome, in the context of rubella, principles
from metapopulation dynamics suggest that these remote
locations below the CCS (depicted on the inset map,
figure 4a) may have a higher burden of CRS pre-vaccination,
as disease-free periods may allow ageing of susceptibles into
their childbearing years, leaving them vulnerable to sub-
sequent rubella introductions [12], an issue that may be
amplified by inequity in vaccination coverage [21].
One way to evaluate the degree to which our measure of
connectivity is dynamically relevant is to evaluate the relation-
ship between average age of infection and remoteness for
districts that are below 1 000 000, and thus expected to be vul-
nerable to stochastic extinction (figure 4b). If our connectivity
index is capturing a measure of relevance to stochastic extinc-
tion, based on simulations of the stochastic dynamics in a
location below the CCS (see the electronic supplementary
material, figure S3), we expect increased variance in the aver-
age age of infection for more remote districts below the upper
bound on the CCS. This is broadly what is observed (figure 4)
and indicates that higher average age of infection can occur in
these less connected districts and potentially poses risks for an
elevated burden of CRS. Qualitatively similar results are
obtained for the lower threshold on the CCS.
3.4. Vaccination and extinction of rubella in Madagascar
Ultimately, the appropriate epidemiological unit for investi-
gating metapopulation dynamics is probably the scale of
cities [29]. The closest available scale in this dataset is the
districts, as mentioned above. However, in the face of
the sparseness of the population in Madagascar, and
under-reporting of rubella, in considering the potential for


































Figure 4. Connectivity, remoteness and rubella dynamics (a) District connectivity (x-axis) plotted against district population size ( y-axis) showing communities
below the lower limit of the CCS report for rubella (350 000, lower horizontal line), and poorly connected (i.e. dotted line showing the bottom quantile of con-
nectedness, taken to correspond to remote locations) on the figure and the inset map in red. The upper limit of the CCS (1 million) is also shown (higher horizontal
line). Connectivity is a relative measure derived from the amount of incoming travel estimated from a gravity model to each district; districts are remote if there is
less travel. (b) For districts below the CCS, mean age of infection ( y-axis) plotted against the index of connectivity (x-axis), with districts that are weakly connected
and below the lower limit of the CCS, but also have experienced a higher average age of infection (and thus might have experienced a higher burden of CRS) shown





 on May 3, 2016http://rsif.royalsocietypublishing.org/Downloaded from scale dynamics. This is equivalent to assuming that each of
the 22 regions is reasonably well mixed, and further subdivi-
sions should broadly act to reduce persistence of rubella in
Madagascar, by reducing the number of locations above the
CCS, so this scale of analysis should be reasonably conserva-
tive. Even at this greater spatial scale, the majority of regions
(55%, 12 out of 22 regions) have populations that are below
the upper end of the CCS range of 1 000 000; a few are also
below the threshold for measles of 350 000 (14%, 3 out of
22 regions).
Given the isolated nature of Madagascar, low burden
of CRS, and increased international and national public
health support for control of vaccine-preventable diseases,
we analysed the potential for rubella elimination, using simu-
lations of regional dynamics of rubella (see the electronic
supplementary material, figures S4 and S5; figure 5). At the
current levels of vaccination coverage, the probability of
rubella elimination, corresponding to zero rubella incidence
in all 22 regions (i.e. points clustered at the top of the bar
charts in figure 5a) after 20 years of vaccination ranges from
15% (at low levels of connectivity) to 8% (at a high level of
connectivity). This probability was estimated as the pro-
portion of simulations (across the 100 simulations) that
went extinct in all 22 regions. If vaccination coverage was
increased to 90% in all locations, the probability of rubella
extinction increases to 39%, regardless of connectivity scalar(from the points clustered at the top of figure 5b). If vacci-
nation coverage is increased in focal, well-connected regions
only, the probability of rubella elimination moves from 20%
at low connectivity and 9% at high connectivity (values
clustered at the top of figure 5c).4. Discussion
With increased support from the Global Alliance of Vaccines,
countries that have previously withheld RCV out of concerns
for the potential paradoxical increase in the burden of rubella
are now considering introduction of the vaccine. This endea-
vour presents an opportunity to reduce the burden of a
preventable disease (CRS), but may also have additional
public health benefits; in particular, that of strengthening
existing measles vaccination programmes [32]. Evaluation
of the effectiveness of introduction of RCV into a specific
country requires an understanding of (i) the current epide-
miology of rubella and burden of CRS; (ii) possible areas
of increased burden given the landscape of vaccination cover-
age; and (iii) likely sources and sinks for localized extinction
and re-introduction. These factors can be combined to evalu-
ate the effectiveness of vaccination strategies for both routine














































Tana, Antsirabe, Toamasina, Manakara, Toliara
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Figure 5. Consequences of vaccination for extinction of rubella in Madagascar showing the proportion of the 22 regions in which rubella is extinct after 20 years of
vaccination across 100 simulations for three levels of the connectivity scalar y . This range of values of y were set such that the associated rescaling for the con-
nectivity matrix estimated from geospatial data resulted in dynamics of rubella in Madagascar that captured the globally reported range of the CCS for rubella (see
the electronic supplementary material, figure S4) across 100 simulations. Results are shown (a) at current reported administrative levels of coverage; (b) for 80, 90
and 95% coverage in all regions and (c) at reported levels of coverage but with an increase to 95% in focal regions (organized in sequence to explore cumulative
effects) whose administrative capitals are indicated in the figure legend. Proportion of simulations in which extinction is achieved is reported in the main text.





 on May 3, 2016http://rsif.royalsocietypublishing.org/Downloaded from We evaluated this public health question in the context of
Madagascar, a country planning to introduce RCV in the
upcoming year (2016). Analysis of rubella data yields results
broadly consistent with other descriptions of rubella epide-
miology, although the characteristic under-reporting often
noted for this infection (which may be so mild as to be
asymptomatic) results in considerable uncertainty in some
of our inference. In particular, the seasonal pattern detected
here does not show strong alignment with school terms
(figure 2b), in contrast with frequently reported patterns
[22,28,33], but uncertainty is sufficiently high such that an
alternate pattern (e.g. alignment with agricultural seasons
with increased rainfall beginning in October–November
[34]) cannot be affirmed with certainty.
A first major concern associated with introduction of RCV
is avoidance of the paradoxical effect, i.e. a reduction in
rubella incidence insufficient to offset the average age of
infection, thus leading to an increase in the burden of CRS
[3]. Our age-structured simulation analyses broadly support
introduction of RCV in Madagascar, particularly if introduc-
tion is accompanied by wide age range campaigns that could
be implemented via the existing two forms of additional
vaccination opportunities discussed above (SIAs and
mother–child health days). When such an additionalvaccination campaign is in place, neither long term nor tran-
sient increases in the CRS burden, as previously observed in
Greece [35] and Costa Rica [36], are observed in simulations
for rubella in Madagascar (including simulations with R0
values as high as 8). These results rest on administrative esti-
mates of routine vaccination coverage. As these estimates are
frequently known to be overestimates [16], we also explored
scenarios of low routine coverage (table 1) and obtained
broadly similar results.
A second major concern associated with introduction of
RCV is potential for amplification of inequities associated
with the metapopulation dynamics of this infection [11], in par-
ticular those associated with heterogeneity in vaccine coverage
[37,38]. The deterministic simulations described above ignore
the role of stochastic dynamics [12], which can interact with
variation in vaccination coverage [11], potentially resulting in
local increases in the burden of CRS. To explore these latter
issues, we also identified all districts both below the CCS for
rubella and weakly connected (remote; figure 4). Variance in
the age of incidence broadly increased with diminishing con-
nectivity, suggesting a role for metapopulation dynamics
(although spatial variance in R0 cannot be excluded) and high-
lighting districts that should be a special focus in evaluating
the consequences of introduction of the vaccine. Whatever
core policy considerations for RCV roll-out
Q1: Will introducing RCV increase the burden of CRS?
Q2: Are there locations where the burden of CRS will increase following
RCV introduction?
Q3: Will introducing RCV result in rubella elimination?
current rubella epidemiology
— transmission characteristics (R0, 
transmission and contact patterns 
over age)




— measles vaccination coverage 
(since RCV is usually introducted 
into measles programmes)
spatial variability
— spatial heterogeneity in rubella 
dynamics
— spatial variability in vaccine 
access
— spatial variability in demography
— human connectivity
— rubella age incidence data 
historical and seasonally 
disaggregated, e.g. weekly
 — fever–rash surveillance
 — rubella IgM serology 
 testing
— rubella IgG serology to revealing 
population immunity
— contact diaries (age patterns)
— national census, surveys
     (demography)
— MOH administrative measles 
vaccination coverage, or measles 
vaccination survey data (e.g. from 
demographic health surveys)
— spatially indexed fever–rash 




— analytical results for R0, etc. [19]
— TSIR for seasonality, R0 [29]
— extrapolation from age serology 
to infer CRS burden [8] or contact 
over age [19]
— age-structured model  
predictions [10] for CRS burden 
following vaccination (figure 3)
process-based estimation 
techniques of vaccination coverage
[38] and its spatial variability 
[37,38]
— meta-population models to  
predict extinction probability 
(figure 5)
— age-structured  
— estimating travel from spatial
     interaction models
meta-population models to 
predict CRS burden following 
key unknowns to clarify existing data sources
modelling to fill knowledge




— geospatial moility data
— subnational demographic data 
vaccination [11]
Figure 6. Considerations for roll-out of RCV in low-income settings following opening of the GAVI funding window including key unknowns; existing data sources;
and statistical and mathematical approaches to leverage this data, to both identify the key unknowns and tackle the core considerations (shown in bold in the final





 on May 3, 2016http://rsif.royalsocietypublishing.org/Downloaded from the underlying cause, districts with higher average age of infec-
tion are more at risk of being associated with a higher CRS
burden.
Having explored the risks of introduction of RCV into
Madagascar, we next investigated positive externalities
specific to Madagascar—in particular, the degree to which
vaccination against rubella might result in elimination of
the virus from the country, a realistic prospect given Mada-
gascar’s unique status as an island nation. Assuming that
current vaccination coverage estimates reasonably reflect the
context in Madagascar, our analysis suggests that the prob-
ability of elimination of rubella with introduction of RCV
might be as high as 15% over 30 years. Improvements in vac-
cination coverage, especially targeted at the major hubs of
travel (i.e. the most connected areas according to the metrics
developed and shown in figure 4) could improve this esti-
mate yet further (figure 5), as well as offer considerable
potential for improving measles control. Nevertheless,
rubella elimination is not a certainty even with extremely
high vaccination coverage across all regions (95%, figure 5).
This suggests that targeted vaccination efforts—where vac-
cine deployment is closely linked to surveillance, either ofcases (i.e. as currently employed in outbreak response vacci-
nation for measles [39]), or more powerfully, of serological
status within the population—are likely to be more effective
components of successful elimination of rubella than blanket
vaccination campaigns across broad spatial scales.
Very few measles cases have been reported over Madagas-
car’s fever–rash surveillance system over the past decade,
despite regular reports of rubella, suggesting that the system
is functioning effectively. These observations also support esti-
mates of administrative coverage, which indicate reasonably
high vaccination coverage against measles in Madagascar cur-
rently, and over the recent past, thus again bolstering the
prospect for elimination of rubella. However, should introduc-
tion of RCV into Madagascar be accompanied by the positive
outcome of elimination of rubella, the risk of a post-
honeymoon outbreak must be an important consideration
[40]—the absence of reported cases does not mean that the
risk of an outbreak is not building. While rubella elimination
will invariably reduce the burden of CRS, there is some
sense in which such elimination presents a double edged
sword—the absence of circulating cases opens the door to





 on May 3, 2016http://rsif.royalsocietypublishing.org/Downloaded from coverage not be maintained at high levels. Susceptible build-
up is particularly problematic for rubella, as the opportunity
for unvaccinated susceptible girls to age into their childbearing
years is of major concern. Rubella incidence or control should
thus be considered across a long time-horizon [14], with
emphasis on maintaining high levels of population immunity
via vaccination over the long term.
The availability of rubella data from the pre-vaccination era
in Madagascar presents a unique opportunity to evaluate the
impact of introduction of RCV into the measles vaccination
programme. This opportunity could be further enriched by
the improvement of current surveillance, as well as collection
of further metrics before, and during, deployment of the vac-
cine [41]. Some very simple and low-cost extensions of the
current system in Madagascar are possible. In particular,
mothers whose children present with fever and/or rash are
currently questioned about the last vaccine a child has
received—with no information about the type of vaccine (e.g.
poliomyelitis and measles). Narrowing this question to specifi-
cally enquire about measles or measles–rubella vaccine would
considerably strengthen this element of reporting. There are
also opportunities to design surveys specifically focused on
this question—e.g. following previous examples for rotavirus
in Malawi [42]. Another question that we did not formally
tackle here—and an aspect not currently under consideration
in the context of roll-out of the vaccine in Madagascar—is the
impact of targeted vaccination of girls or women; previous
work has indicated that this may further reduce the risk in
an increase in the CRS burden [10] and is a prospect worth con-
sidering further in the context of rubella in Madagascar.
Here, we lay out the array of core questions for countries
considering introduction of RCV following the opening of
the GAVI funding window (figure 6), and address them
using data fromMadagascar. Our analysis indicates that vacci-
nation campaigns will be essential upon introduction of RCV
to ensure that long- and short-term increases in the burdenof CRS are avoided. It is generally recognized that in the
longer term, strengthening of routine programmes and
reduced dependence on vaccination campaigns is desirable
[43]. If such improvements in routine immunization can be
achieved, our results also indicate potential for Madagascar
to eliminate rubella over the longer term, especially if targeted
vaccination is also deployed. This positive outcome is never-
theless one that will require continued public health vigilance.Authors’ contributions. Conceived and designed the experiments:
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